Parabacteroides distasonis promotes CXCL9 secretion of tumor-associated macrophages and enhances CD8+T cell activity to trigger anti-tumor immunity against anti-PD-1 treatment in non-small cell lung cancer mice

被引:0
|
作者
Zhijun Fan [1 ]
Zheng Yi [1 ]
Sheng Li [2 ]
Junjun He [2 ]
机构
[1] Department of Cardiothoracic Surgery, The People’s Hospital of Liuyang, Changsha
[2] Department of Gastrointestinal Surgery, The Central Hospital of Shaoyang, Shaoyang
关键词
CXCL9; Non-small cell lung cancer; Parabacteroides distasonis; PD-1; Tumor-associated macrophages;
D O I
10.1186/s12896-025-00963-9
中图分类号
学科分类号
摘要
Background: Parabacteroides distasonis (P. distasonis) could regulate inflammatory markers, promote intestinal barrier integrity, and block tumor formation in colon. However, the regulatory effect of P. distasonis on non-small cell lung cancer (NSCLC) remains unknown. This study aimed to investigate the regulatory effect of P. distasonis on NSCLC and its impact on tumor immunity. Methods: We first established a mouse model of Lewis lung cancer, and administered P. distasonis and intrabitoneal injection of anti-mouse PD-1 monoclonal antibody to assess the impact of P. distasonis on tumor immunity, and mouse intestinal barrier. Then, we explored the effect of P. distasonis on CD8+T cells and CXCL9 secretion mediated by tumor-associated macrophages (TAM). We used the TLR1/2 complex inhibitor CPT22 to evaluate its effect on macrophage activation. Finally, we explored the effect of P. distasonis on CD8+T cells and CXCL9 secreted by TAM in vivo. Results: In vivo, P. distasonis enhanced anti-tumor effects of anti-PD-1 in NSCLC mice, improved intestinal barrier integrity, recruited macrophages, and promoted M1 polarization. In vitro, CD86 and iNOS levels in BMDM were elevated and CD206 and Arg1 levels were suppressed in membrane fraction of P. distasonis (PdMb) group in comparison to Control group. With additional CPT22 pre-treatment, the levels of CD86 and iNOS in BMDM were reduced, and the levels of CD206 and Arg1 were increased. Compared to PBS group, P. distasonis group exhibited higher proportion of CD8+T cells in tumor tissues, along with increased positive proportion of GZMB and IFN-γ in CD8+T cells. Additionally, in comparison to Control group, PdMb group showed an elevated proportion of GZMB+T and IFN-γ+T cells within CD8+T cells, and secretion of IFN-γ, TNF-α, perforin, and GZMB in CD8+T cell supernatant increased. Moreover, the proportion of CXCL9+F4/80+ macrophages in tumor tissues was higher in P. distasonis group compared to PBS group. In comparison to Control group, CXCL9 protein level in BMDM and CXCL9 secretion level in BMDM supernatant were increased in PdMb group. Finally, P. distasonis enhanced CD8+T cell activity by secreting CXCL9 from macrophages in vivo. Conclusions: P. distasonis promoted CXCL9 secretion of TAM and enhanced CD8+T cell activity to trigger anti-tumor immunity against anti-PD-1 treatment in NSCLC mice. © The Author(s) 2025.
引用
收藏
相关论文
共 35 条
  • [31] Continuation of anti-PD-1 therapy plus physician-choice treatment beyond first progression is not associated with clinical benefit in patients with advanced non-small cell lung cancer
    Wang, Yixing
    Fu, Sha
    Zhang, Xuanye
    Du, Wei
    Luo, Linfeng
    Jiang, Yongluo
    Zhou, Yixin
    Zhao, Yuanyuan
    Yang, Yunpeng
    Zhao, Hongyun
    Fang, Wenfeng
    Huang, Yan
    Zhang, Li
    Hong, Shaodong
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [32] CXCR6-positive circulating mucosal-associated invariant T cells can identify patients with non-small cell lung cancer responding to anti-PD-1 immunotherapy
    Qu, Jingjing
    Wu, Binggen
    Chen, Lijun
    Wen, Zuoshi
    Fang, Liangjie
    Zheng, Jing
    Shen, Qian
    Heng, Jianfu
    Zhou, Jianya
    Zhou, Jianying
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2024, 43 (01)
  • [33] RETRACTED: Physcion 8-O--Glucopyranoside Exerts Anti-Tumor Activity Against Non-Small Cell Lung Cancer by Targeting PPAR (Retracted article. See vol. 304, pg. 2903, 2021)
    Du, Youyi
    Lv, Zhuqing
    Sun, Debin
    Li, Yuan
    Sun, Lei
    Zhou, Jiafeng
    ANATOMICAL RECORD-ADVANCES IN INTEGRATIVE ANATOMY AND EVOLUTIONARY BIOLOGY, 2019, 302 (05): : 785 - 793
  • [34] First exploration of the on-treatment changes in tumor and organ uptake of a radiolabeled anti PD-L1 antibody during chemoradiotherapy in patients with non-small cell lung cancer using whole body PET
    Pouw, Johanna E. E.
    Hashemi, Sayed M. S.
    Huisman, Marc C.
    Wijngaarden, Jessica E.
    Slebe, Maarten
    Oprea-Lager, Daniela E.
    Zwezerijnen, Gerben J. C.
    Vugts, Danielle
    Ulas, Ezgi B.
    de Gruijl, Tanja D.
    Radonic, Teodora
    Senan, Suresh
    van Oordt, C. Willemien van der Houven
    Bahce, Idris
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (02)
  • [35] Pretreatment Fibrinogen-Albumin Ratio (FAR) Associated with Treatment Response and Survival in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Anti-PD-1 Therapy Plus Platinum-Based Combination Chemotherapy
    Yuan, Chengliang
    Huang, Meifang
    Wang, Huilin
    Jiang, Wei
    Su, Cuiyun
    Zhou, Shaozhang
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 377 - 386